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Introduction
The Aurora A (AurA) kinase is overexpressed in a high percent­
age of tumors arising in breast, colon, ovary, and other tissues 
(Bischoff et al., 1998; Zhou et al., 1998; Tanaka et al., 1999; 
Tanner et al., 2000; Goepfert et al., 2002) and functions as an 
oncogene when exogenously expressed in cell line models for 
cancer development (Tatsuka et al., 1998; Meraldi et al., 2002; 
Anand et al., 2003; Zhang et al., 2004). In normal cells, one im­
portant function of AurA is as a centrosomally localized regula­
tor of entry into and passage through mitosis (Marumoto et al., 
2005; Pugacheva and Golemis, 2006); defects in these roles 
likely explain the supernumerary centrosomes and aneuploidy 
that characterize tumor cells with overexpressed AurA. Many 
studies of AurA performed in mammals and model organisms 
have shown that AurA kinase activity increases sharply at the 
G2/M boundary and is highest through M phase in normal cells 
based on interactions with partner proteins, including TPX2, 
NEDD9/HEF1, and others (Bayliss et al., 2003; Pugacheva and 
Golemis, 2005; Hutterer et al., 2006). Activated AurA detected 
in interphase cancer cells was initially attributed to a patho­
logical disease state, unreflective of the role for AurA in normal 
cells. However, convergence of several lines of investigation has 
begun to greatly extend known roles for AurA.
Initial evidence for nonmitotic AurA functions arose from 
a  study  of  the  Chlamydomonas  reinhardtii  aurora  protein   
kinase, a distant orthologue of AurA in the green algae C. rein-
hardtii (Pan et al., 2004). This work revealed that C. reinhardtii 
aurora protein kinase is activated and regulates resorption of the 
flagella in response to cues for mating or environmental ionic 
stress, rather than cell cycle cues. Subsequently, our group es­
tablished that serum growth factors induce AurA activation at 
the basal body of the cell cilium (a structure analogous to the 
flagellum) in noncycling G0/G1 mammalian cells causing AurA­ 
and  NEDD9­dependent  ciliary  resorption  (Pugacheva  et  al., 
2007). We further showed that release of Ca
2+ from the ER to 
the cytoplasm transiently activated AurA, based on induced   
direct Ca
2+­calmodulin (CaM) binding to AurA (Plotnikova 
et al., 2010). Independently, other groups have found that atypical 
PKC activates AurA, allowing AurA to phosphorylate NDEL1 
and promote microtubule remodeling during neurite extension 
(Mori et al., 2009). AurA has also been found to directly phos­
phorylate Par­6, which together with atypical PKC and Par­3 
regulates asymmetric cell division and cell polarity (Ogawa et al., 
2009; Yamada et al., 2010). These nonmitotic activities of AurA 
likely also contribute to deregulation of growth in tumor cells 
overexpressing AurA. For example, interphase­active AurA 
M
ost studies of Aurora A (AurA) describe it as a 
mitotic centrosomal kinase. However, we and 
others have recently identified AurA functions 
as diverse as control of ciliary resorption, cell differentia-
tion, and cell polarity control in interphase cells. In these 
activities, AurA is transiently activated by noncanonical 
signals,  including  Ca
2+-dependent  calmodulin  binding. 
These and other observations suggested that AurA might 
be involved in pathological conditions, such as polycystic 
kidney disease (PKD). In this paper, we show that AurA is 
abundant in normal kidney tissue but is also abnormally 
expressed  and  activated  in  cells  lining  PKD-associated 
  renal cysts. PKD arises from mutations in the PKD1 or 
PKD2 genes, encoding polycystins 1 and 2 (PC1 and PC2). 
AurA binds, phosphorylates, and reduces the activity 
of  PC2, a Ca
2+-permeable nonselective cation channel 
and, thus, limits the amplitude of Ca
2+ release from the 
endoplasmic reticulum. These and other findings suggest 
AurA may be a relevant new biomarker or target in the 
therapy of PKD.
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or in the loops of Henle. This expression pattern is similar to 
that previously reported for PC2, which is also abundant in the 
convoluted tubules and collecting ducts, although PC2 is also 
abundant in the loops of Henle (Foggensteiner et al., 2000). 
AurA staining was generally detectable in the cytoplasm but also 
intensely concentrated in the nucleus of some cells, with the 
greatest number of nuclear­staining cells associated with the 
distal convoluted tubules. Suggestively, a subset of these AurA­
positive structures also stained positively for T
288­phospho–AurA 
(phAurA), indicating activity across adjacent groups of non­
mitotic cells (Fig. 1 b and Fig. S1 a); again, the most intense stain­
ing was associated with distal convoluted tubules and collecting 
ducts. As further confirmation, we also examined AurA and 
phAurA expression in mouse renal tissue (Fig. 1, c and d; and 
Fig. S1 a) and found a similar expression and activation pattern.
AurA is typically described as solely localized to the   
centrosome or centrosomally derived ciliary basal body and   
otherwise hard to detect in noncycling normal mammalian cells. 
In this context, the fact that cancerous cells with overexpressed 
AurA have an extensive diffuse pool of cytoplasmic AurA is 
thought to support the interaction of AurA with substrates with 
which it does not normally associate (discussed in Pugacheva 
and Golemis, 2006). However, we find AurA is intrinsically 
abundant in HK­2 cells, a well­differentiated cell line derived 
from the proximal tubules of the human kidney (Ryan et al., 
1994), in primary nontransformed human ovarian surface epi­
thelial cells (Fig. 2 a) and in noncycling primary mouse kidney 
cells (Fig. S1 b). Moreover, siRNA depletion experiments of HK­2 
cells followed by detection with two different antibodies to AurA 
(Fig. 2 b and not depicted) indicated the presence of a significant 
cytoplasmic pool of AurA in interphase HK­2 cells in addition to 
the anticipated concentrated pool of AurA at centrosomes.
We next investigated whether AurA expression, localiza­
tion, or activation was specifically altered in the context of PKD. 
Examination of eight primary cysts derived from eight patients 
with PKD (Fig. 2 c) revealed prominent AurA staining specifi­
cally within the epithelial cells lining the cyst but not the fibrotic 
tissue. This was particularly noticeable in small and midsized 
cysts and in areas of hyperproliferative epithelial cells adjacent 
to cysts and was accompanied by a strong T
288­phAurA signal, 
indicating kinase activation.
AurA negatively regulates basal cellular 
Ca
2+ levels and PC2-dependent  
Ca
2+ channel activity
We have shown that Ca
2+ transiently activates AurA (Plotnikova 
et al., 2010), and our data indicate that in the abnormal Ca
2+ sig­
naling environment associated with PKD renal cysts (Anyatonwu 
and Ehrlich, 2004), AurA expression is enhanced. We hypothe­
sized that AurA might reciprocally influence cellular Ca
2+ levels 
in a typical signaling feedback circuit (Sneppen et al., 2010).   
Indeed, treatment of HK­2 and LLCPK1 kidney cells with the 
AurA inhibitor PHA­680632 for 3 h significantly increased basal 
levels of Ca
2+, based on measurement of the fluorescence of the 
cytoplasmic Ca
2+­binding dye Fluo­4 (Fig. 3 a; Cai et al., 2004). 
Similar results were obtained after depletion of AurA by siRNA 
in LLCPK1 cells (Fig. 3 b) and HEK293 cells (not depicted).
phosphorylates and promotes the activity of the RalA GTPase, 
an epidermal growth factor receptor/Ras effector important in 
many cancers (Wu et al., 2005). Loss of cilia associated with 
high level AurA expression would indirectly impact the func­
tionality of the cilia­dependent and cancer­relevant signaling 
cascades, such as those involving Hedgehog (Wong et al., 2009).
Pathological conditions of the kidney include renal cell 
carcinoma, which has been linked to elevated AurA expres­
sion (Kurahashi et al., 2007). However, beyond high expres­
sion in kidney tumors, AurA (Kurahashi et al., 2007) and its 
partner NEDD9 (Law et al., 1996; Pugacheva and Golemis, 
2005, 2006) have been predicted to be abundant in normal   
kidneys. Interestingly, formation of renal cysts is very strongly 
linked to defects in planar cell polarity control (Fischer et al., 
2006; Bacallao and McNeill, 2009), and the changes in Ca
2+ 
signaling induced by autosomal dominant polycystic kidney 
disease (PKD; ADPKD)–associated mutations in the PKD1 
and PKD2 genes, encoding the PC1 transmembrane flow re­
ceptor and the PC2 calcium channel (Hanaoka et al., 2000; 
Wilson, 2004; Pan et al., 2005; Benzing and Walz, 2006).   
Interestingly, an antibody cross­reactive with NEDD9 and its 
paralogue BCAR1/p130Cas has been reported as detecting 
one of these proteins in a complex with PC1 (Geng et al., 
2000). NEDD9 binds directly to the differentiation regulatory 
protein Id2 (Law et al., 1999), which in turn has been reported 
to bind directly to PC2 and mediate proliferative signals in 
PKD (Li et al., 2005). Cumulatively, these studies led us to 
hypothesize that changes in AurA and/or NEDD9 expression 
or activity might have a role in signaling processes associated 
with development of renal cysts.
Based on these and other studies, we have investigated 
AurA in kidney signaling relevant to cystogenesis. Our work 
demonstrates that AurA is abundant and frequently active in 
normal renal tissue and hyperactivated in early renal cysts asso­
ciated with PKD. We show that low concentrations of drugs that 
inhibit AurA activity augment basal intracellular Ca
2+ levels in 
renal cells and PC2­dependent Ca
2+ release. We also find that 
AurA directly binds and phosphorylates PC2, which may pro­
vide a mechanism by which AurA inhibition limits PC2 Ca
2+ 
channel activity. ADPKD affects as many as 1 in 500 individ­
uals and currently has few viable treatment options. The results 
described here may suggest potential clinical applications of 
AurA and its inhibitors in better diagnosing or treating this seri­
ous disease.
Results
Abundant AurA expression and activity  
in normal kidney tissue and cells and in 
renal cysts
If AurA has in vivo, noncell cycle function relevant to PKD, 
AurA should be detectable and potentially active in nondividing 
renal tissue. Immunohistochemical analysis of primary human 
kidney specimens readily detected AurA in multiple substruc­
tures (Fig. 1 a and Fig. S1 a). AurA was most concentrated in 
cells of the proximal and particularly distal convoluted tubules and 
in the collecting ducts. AurA was not detectable in the glomerulus 1023 Aurora A influences calcium signaling • Plotnikova and Golemis
level (Qian et al., 2003; Geng et al., 2008). To test whether 
AurA might modulate intracellular Ca
2+ level through regula­
tion of the PC2 calcium channel, we used Pkd2
+/ and Pkd2
/ 
kidney cell lines derived from mutant mice (Grimm et al., 2003; 
Geng et al., 2008). Pkd2
/ cells have a reduced level of basal 
The PC2 Ca
2+ channel is abundant and active in kidney 
cells. In PKD, PC2 has abnormally reduced function as a result 
of direct mutation or mutation of its upstream partner PC1 (with 
which it heterodimerizes at cilia), resulting in abnormal Ca
2+ 
homeostasis. Cell lines lacking PC2 have reduced basal Ca
2+ 
Figure 1.  Abundant AurA expression and activity in normal kidney tissue and cells. (a and b). Immunohistochemical visualization of endogenous total 
AurA (a) or phAurA (b) in normal human kidney tissue. Typical fields from the cortical (left) and medullary regions (center) are shown. PCT, proximal con-
voluted tubules; DCT, distal convoluted tubules; CD, collecting ducts; LH, thin segments of Loops of Henle; GM, glomerulus. (c and d) Immunohistochemical 
visualization of endogenous AurA (c) or phAurA (d) in normal mouse kidney tissue. (right) Sections stained with antibody to AurA preincubated with blocking 
peptide and, for phAurA, negative control IgG.JCB • VOLUME 193 • NUMBER 6 • 2011   1024
An equivalent response was seen in cells in which histamine was 
used to induce PC2 channel activity (Fig. S1, c–e). Recip­
rocally, treatment of PC2­transfected HEK293 cells with the 
AurA  inhibitor  PHA­680632  (Soncini  et  al.,  2006)  signifi­
cantly enhanced the amplitude of release (Fig. 3, g and h; and 
Fig. S3 b). Similar results were obtained using HK­2 cells sta­
bly overexpressing PC2 (Fig. S1, f–h) and in cells treated with a 
separate small molecule inhibitor of AurA, C1368 (Fig. S1, i–k).   
In PC2­overexpressing HK­2 cells with AurA depleted by siRNA, 
AVP­induced Ca
2+ release was significantly increased to a degree 
comparable with that seen with treatment with AurA inhibitory 
drugs (Fig. 3, i and j; Fig. S1 l; and Fig. S3 c). Together, these data 
strongly implicated AurA as a regulator of PC2 channel activity.
PHA-680632 enhances PC2 activity at 
low inhibitory concentration (IC) values
Given that one consequence of mutations in PKD1 is to reduce 
PC2 activation (Nauli et al., 2003), if AurA inhibition enhances 
PC2 activity, this might suggest a clinical strategy in PKD arising 
from mutations in PKD1 (in which the PKD2 gene is structurally 
Ca
2+ compared with Pkd2
+/ cells as previously described (Fig. 3 c; 
Geng et al., 2008). Treatment with the AurA inhibitor PHA­
680632 significantly increased intracellular Ca
2+ levels in both 
Pkd2
+/ and Pkd2
/ cells but was less active in Pkd2
/ cells 
(Fig. 3 c), whereas the levels of AurA were equivalent in both 
Pkd2
+/ and Pkd2
/ cell lines (Fig. S1 b). Those data implied 
that AurA influenced basal Ca
2+ in a process at least partially 
dependent on intact PC2. We also further demonstrated that 
PHA­680632 did increase basal Ca
2+ level in human kidney cell 
lines with a mutated PKD1 gene but an intact PKD2 gene (Fig. 3 d; 
Loghman­Adham et al., 2003), as would be expected if the AurA 
target were downstream of PKD1.
To more directly test whether AurA regulates the PC2 
Ca
2+ channel, we transiently transfected HEK293 cells with PC2 
together with RFP­AurA or an RFP negative control and mea­
sured fluorescence of the cytoplasmic Ca
2+­binding dye Fluo­4   
after arginine vasopressin (AVP) treatment, comparing the   
amplitude and duration of Ca
2+ release (Fig. 3, e and f; and 
Fig. S3 a). Cotransfected RFP­AurA reduced the amplitude of 
the Fluo­4 signal to 50% of that in control­transfected cells.   
Figure 2.  Abnormal AurA expression and activity in renal cysts. (a) Western blot analysis of total AurA levels in human cells: HEK293, human embryonic 
kidney cells; HK-2, adult human kidney epithelial cells; RPE1, immortalized retinal pigment epithelial cells; HOSE, primary human ovarian surface epithelial 
cells; MCF10A, immortalized mammary epithelial cells. For all experiments, -actin was used as a loading control. (b) Immunofluorescence of HK-2 cells 
treated with siRNA to deplete AurA (siAurA) or with control scrambled siRNA (Scr). Bar, 10 µm. (c) Immunohistochemical detection of AurA and phAurA 
in renal cysts from PKD patients. Epithelial cells lining cysts and cyst-associated areas of hyperproliferative epithelial cells, but not cyst-associated fibrotic 
tissue, consistently demonstrate strong staining. Molecular masses are given in kilodaltons.1025 Aurora A influences calcium signaling • Plotnikova and Golemis
explanation for the difference in results could be that PHA­
680632 was used for only a 2­h pretreatment in Ca
2+ release exper­
iments but must be sustained in culture medium for 3 d in IC50 
determinations: greater compound decay in the latter experiments 
might stipulate higher initial dosing concentrations. However, in 
parallel experiments in which PHA­680632 was added to media 2 
or 24 h before AVP treatment, significantly greater enhancement 
of PC2 activity occurred with the longer 24­h preincubation than 
the 2­h incubation used for other experiments, suggesting drug sta­
bility was not an issue (Fig. 4, b and c). These data suggest that 
AurA may be a useful target in modulating PC2 activity in vivo.
AurA interacts directly with PC2
The bulk (>95%) of intracellular PC2 associates with the ER 
and mediates Ca
2+ release to the cytoplasm (Cai et al., 1999). To 
assess whether there might be direct interactions between AurA, 
intact). In vivo, Aurora kinase inhibitors have marked effects as 
cell cycle inhibitors (Gautschi et al., 2008), which is relevant 
to their action in cancer therapy, raising the possibility of toxic 
side effects if these agents were used in PKD. However, a re­
cent study has suggested that the cytotoxic effects of Aurora 
kinase inhibitors used in vivo at least partially reflects their cross­
reactive inhibition of Aurora B rather than AurA, which occurs 
at higher concentrations (discussed in Gautschi et al., 2008).
We compared the doses of PHA­680632 required to in­
hibit cell growth with those required to enhance PC2 signals. In 
HK­2 cells, the half­maximal IC (IC50) value for PHA­680632 is 
3.25 µM, whereas the 500­nM concentration used for the afore­
mentioned experiments represents an IC5 value (Fig. 4 a). In con­
trast, an approximately twofold enhancement of AVP­induced 
Ca
2+ release is seen whether PHA­680632 is used either at 3.25 µM 
or at 500 nM (Fig. 4, b and c; and Fig. S3 d). One possible 
Figure 3.  AurA negatively regulates basal cellular Ca
2+ levels and PC2-dependent Ca
2+ channel activity. (a) Effect of PHA-680632 on basal intracellular 
Ca
2+ in HK-2 and LLCPK1 cells. Cells were loaded with 5 µM Fluo-4 AM, which autofluoresces upon binding cytoplasmic Ca
2+. Cells were treated with 
PHA-680632 (PHA) to inhibit Aurora kinase, or DMSO vehicle control. *, P = 0.0024; **, P = 0.0013. (b) Basal Ca
2+ level in LLCPK1 cells treated with 
siRNA to deplete AurA (siAurA) versus scrambled siRNA control (Scr). *, P = 0.00056. (c) Basal Ca
2+ levels were assessed in Pkd2
/ and Pkd2
+/ cells 
treated with PHA-680632 or DMSO. *, P = 0.0132; **, P = 0.0209 (in comparison with DMSO-treated Pkd2
+/ cells); and P > 0.05 (NS) in comparison 
with DMSO-treated Pkd2
/ cells. (d) Basal Ca
2+ levels were assessed in two PKD1 mutant cell lines, WT9-7 and WT9-12, treated with PHA-680632 or 
DMSO. *, P = 0.0098; **, P = 0.0107. For a–d, all data are expressed as the means ± SEM from at least three independent experiments (n > 50 in each 
experiment). (e) HEK293 cells transiently cotransfected 48 h previously with plasmids expressing PC2 and AurA-RFP or control RFP were loaded with 5 µM 
Fluo-4 AM before analysis. Immunofluorescence was measured before and after addition of AVP (indicated by arrows in e, g, and i). Data are presented as 
the F/F0 ratio, indicating increase in signal over unstimulated cells. F, fluorescence intensity; F0, baseline fluorescence intensity. (f) For this and subsequent 
experiments, the mean increase in amplitude (±SEM) of AVP-induced cytoplasmic Ca
2+ transients was calculated from n > 50 RFP-positive cells in each of 
three experiments. The asterisks shows that, for AurA-RFP, amplitude decreased versus RFP controls; P = 0.008. Alternative analysis as AUC is shown in   
Fig. S3 a. (g) HEK293 cells transfected 48 h previously with a plasmid expressing PC2 or vector control and pretreated for 2 h with 500 nM PHA-680632 
or DMSO vehicle were analyzed as in e. (h) Quantification of data in f. The asterisk indicates that PHA-680632 increased amplitude of signal versus 
DMSO; P = 0.0007. Analysis as AUC is shown in Fig. S3 b. (i) siRNA depletion of AurA in HK-2 cells increases amplitude of Ca
2+ release versus scrambled 
control. (j) Quantification shows significant difference in amplitude (*, P = 0.0055). Analysis as AUC is shown in Fig. S3 c.JCB • VOLUME 193 • NUMBER 6 • 2011   1026
for positively regulating PC2 Ca
2+ channel activity (Cai et al., 
2004). We identified a strongly consensus candidate AurA phos­
phorylation motif (Ferrari et al., 2005) at residue S829 (RRGSI), 
adjacent to the ER­targeting domain, and a less favorable motif 
at residue S944 (PRSSR). We established that recombinant acti­
vated AurA phosphorylated the PC2 C terminus in vitro (Fig. 6 b). 
AurA phosphorylation of PC2 was enhanced by interactions with 
NEDD9 (Pugacheva and Golemis, 2005) in contrast to AurA phos­
phorylation of the control substrate MBP, which was unaffected 
(Fig. 6 c). AurA phosphorylation of PC2 was separately enhanced 
by inclusion of CaM and Ca
2+ in in vitro reactions (Fig. 6 d).
We next compared the ability of AurA to phosphorylate 
a wild­type PC2 C terminus versus derivatives with S→A mu­
tations in the S829, S944, or CK2 motifs or combinations of 
these mutations (Fig. 6, e and f). An S829A mutation greatly 
reduced AurA  phosphorylation  of  PC2,  resulting  in  levels 
close to the background GST negative control, whereas S944A 
and S812A had no effect on this phosphorylation, either in­
dependently or in combination with S829A. By comparison, 
CK2 phosphorylation was reduced to a comparable degree 
solely by mutation of the S812 residue, whereas CK2 phos­
phorylation of PC2 was not affected by the presence of S829A 
or S944A mutations (Fig. 6, g and h). To investigate the in vivo 
phosphorylation of the S829 site, we exploited the fact that 
this site is quite similar to the general PKA substrate con­
sensus (RRxS). Phospho­PKA substrate antibody recognized 
PC2, but not S829A­mutated PC2, in transiently transfected 
HEK293 cells (Fig. 6, i and j). Importantly, cotransfection of 
constitutively active AurA (T288D) increased phosphoryla­
tion of this site, whereas treatment of cells with an AurA in­
hibitor (PHA­680632), but not a PKA inhibitor (H89), reduced 
in vivo phosphorylation. Similar results were obtained using 
two additional small molecule inhibitors of AurA and after 
depletion of either AurA or NEDD9 by siRNA (Fig. S2, d and e). 
Those data indicate that full­length PC2 is phosphorylated   
in vivo at S829.
its previously defined partner and activator NEDD9 (Pugacheva 
and Golemis, 2005), and PC2, we first established that endog­
enous AurA and PC2 coimmunoprecipitated from HK­2 cells 
(Fig. 5 a, left) and from primary kidney lysate (Fig. 5 a, middle). 
Furthermore, the coimmunoprecipitation was clearly observed 
in lysates prepared from Pkd2
+/ cells but not in lysates from 
Pkd2
/ cells (Fig. 5 a, right). We next cotransfected AurA with 
the GFP­tagged PC2 cytoplasmic C­terminal domain (PC2­CT, 
aa 779–968) into HEK293 kidney cells. Overexpressed AurA 
and PC2­CT coimmunoprecipitated (Fig. 5 b and Fig. S2 a). 
Furthermore, in a defined in vitro system, recombinant purified 
full­length AurA pulled down GST­fused PC2­CT (Fig. 5 c and 
Fig. S2 b), interacting separately with both the AurA regulatory 
and catalytic domains (Fig. 5 d). The PC2 C terminus contains 
the primary sites for interaction with PC1 (aa 832–895). AurA 
did not compete with PC1 for binding to PC2 (Fig. 5 e), sug­
gesting the utilization of distinct binding sites on PC2.
Finally, in contrast to the results with AurA, although over­
expressed NEDD9 and PC2 coimmunoprecipitated (Fig. 5 f), no 
interaction was seen between endogenous NEDD9 and PC2 or 
the two purified proteins in vitro system (not depicted). However, 
the presence of NEDD9 enhances the interaction between AurA 
and PC2, as siRNA depletion of NEDD9 significantly depleted 
the degree of coimmunoprecipitation between AurA and PC2­CT 
from HEK293 cells overexpressing these two proteins (Fig. S2 c). 
Together, these data suggested a strong and direct interaction be­
tween AurA and the PC2 C terminus and a significantly weaker 
or indirect interaction between NEDD9 and PC2 that neverthe­
less contributed to efficient interactions between AurA and PC2.
AurA phosphorylates PC2 on C-terminal 
residue S829
Besides the PC1 interaction motif, the PC2 C terminus (Fig. 6 a) 
encompasses an EF hand, Ca
2+­binding motif (aa 754–782), and 
ER­targeting sequences (aa 787–820; Giamarchi et al., 2006). 
A S812 CK2 (casein kinase 2) phosphorylation site is important 
Figure 4.  PHA-680632 enhances PC2 activity at low IC values. (a) IC50 curve for PHA-680632 (PHA) treatment of HK-2 cells stably expressing PC2. Cell 
viability was detected by Alamar blue assay 72 h after treatment. (b) HK-2 cells stably expressing PC2 were treated with DMSO or with PHA-680632 at 
concentrations of 0.5 or 3.25 µM for 2 or 24 h before AVP stimulation and determination of the F/F0 ratio. Addition of AVP is indicated by the first arrow. 
(c) Quantification of relative F/F0 amplitude of data in b. Difference between the double asterisks and single asterisks is significant, P = 0.0022; the dif-
ference between the single asterisks is not significant. Analysis as AUC is shown in Fig. S3 d. F, fluorescence intensity; F0, baseline fluorescence intensity. 
Error bars indicate SEM.1027 Aurora A influences calcium signaling • Plotnikova and Golemis
with the ER of cells expressing these mutants invariably with an 
abnormal aggregated morphology within 24 h (Fig. S2 h) and 
dying within 48–72 h of transfection or transduction. This limi­
tation made it impossible to reliably assess the consequence of 
the S829A mutation on PC2 channel activity against a context 
of dying cells.
Discussion
The work presented here reveals a completely novel activity of 
AurA in the control of cellular homeostasis for calcium. We 
have previously shown that transient stimuli, such as AVP or 
histamine, trigger Ca
2+ release to the cytoplasm, inducing CaM 
binding and autoactivation of AurA, which is marked by AurA 
We have analyzed the consequences of AurA phosphory­
lation on PC2 expression, localization, and activity. PC2 is known 
to localize to the ER membrane, ciliary membrane, and plasma 
membrane. PC2 localized to the ER and to cis portions of the 
Golgi apparatus are sensitive to endoglycosidase H cleavage, 
whereas plasma membrane– and cilia­localized forms of PC2 
are not (Cai et al., 1999; Koulen et al., 2002). The AurA inhibi­
tor PHA­680632 did not affect the overall abundance of PC2 or 
the pool size of endoglycosidase H–cleavable PC2, whether in 
ciliated or nonciliated HK­2 cells (Fig. S2 f). Subsequent 
  immunofluorescence analysis indicated the degree of localization 
of the S829A mutant to the ER and cilia is comparable with that 
of wild­type PC2 (Fig. S2, g and h). However, the mutation of the 
AurA phosphorylation site significantly affected ER integrity, 
Figure 5.  AurA interacts directly with PC2. (a) Antibody to AurA or control IgM was used for immunoprecipitation (IP) from HK-2 cells (left), mouse kidney 
lysates (middle), or PKD2
/ and PKD2
+/ cells (right) followed by Western blotting with antibodies to AurA or PC2 (YCC2) as indicated. The strong band 
migrating at 110 kD represents native PC2, with faster migrating bands reflecting degradation products and slower migrating bands showing glycosyl-
ated species. (b) Antibody to AurA was used for immunoprecipitation from whole-cell lysates (WCL) transfected with plasmids expressing AurA and either 
GFP-PC2779–968 or GFP followed by Western blotting with the indicated antibodies. Reverse orientation immunoprecipitation is shown in Fig. S2 f. (c) Anti-
body to AurA was used in immunoprecipitation from the in vitro mixture containing GST-PC2779–968 or GST only and recombinant His-AurA. CB indicates 
Coomassie blue staining of starting material. Reverse orientation pull-down is shown in Fig. S2 g. (d) RFP-fused catalytic (cat; aa 132–403) and noncatalytic 
(noncat; aa 1–131) domains of AurA or full-length (FL) AurA-RFP coexpressed with Flag-PC2779–968 into HEK293 cells and immunoprecipitated with the 
Flag antibody followed by Western blotting with the indicated antibodies. (e) HEK293 cells were cotransfected with plasmids expressing combinations of 
GFP, GFP-PC2779–968, or Flag-PC1-CT4191–4302 and AurA as indicated. Cell lysates were immunoprecipitated using the anti-GFP antibody and visualized with 
antibodies indicated in the Western blot analysis. (f) Plasmids expressing HA-NEDD9, HA-BioB, and GFP-PC2779–968 were transfected into HEK293 cells, 
cell lysates were immunoprecipitated with the antibody to GFP, and Western blotting was performed with the indicated antibodies. The asterisk indicates 
immunoglobulin heavy chain. Molecular masses are given in kilodaltons.JCB • VOLUME 193 • NUMBER 6 • 2011   1028
AurA binds and phosphorylates PC2 at S
829, with AurA phos­
phorylation of PC2 observed both in defined in vitro reactions 
and in cells. NEDD9 contributes to the specific interaction of 
S
51  phosphorylation  (Plotnikova  et  al.,  2010). We  have  now 
found that AurA negatively regulates the basal Ca
2+ level of renal 
cells and PC2­dependent Ca
2+ release. We have also shown that 
Figure 6.  AurA phosphorylates PC2 on C-terminal residue S829. (a) Structural motifs on PC2 C-terminal (CT) domain include PC1-binding motif (coiled-coil 
domain; aa 832–895), an EF hand for Ca
2+ binding (EF-hand; aa 754–782), and ER-targeting sequences (aa 787–820). Location of assessed sites for 
CK2 (S812) and AurA (S829 and S944) phosphorylation are indicated. NT, N-terminal. (b) Bacterially expressed GST-PC2779–968 or GST-NEDD91–363 and 
MBP (positive controls) or histone H1 (H1) were incubated with recombinant active AurA kinase in an in vitro kinase assay with -[
32P]ATP. The reactions 
were resolved by SDS-PAGE and analyzed by autoradiography, Coomassie blue (CB) staining, and Western blotting with the antibody to AurA. (c) Experi-
ment as in b, except GST-NEDD91–363 was included in the indicated reactions, and relative phosphorylation of PC2 and MBP were calculated (graph). Data 
are expressed as mean values ± SEM of three experiments. *, P < 0.001. For analysis, phosphorylation of PC2 and MPB was first normalized to total PC2 
and total MBP and then further normalized to AurA levels. The boxes indicate phosphorylated species of the C-terminal tail of PC2. (d) Bacterially expressed 
GST-PC2779–968 was incubated with recombinant preactivated AurA (AurA active) or AurA purified from baculovirus in an in vitro kinase assay in the pres-
ence or absence of PC2, CaM, and Ca
2+ as indicated. (top) autoradiography; (bottom) Western blots with the indicated antibodies. (e and f) GST-fused 
derivatives of PC2779–968 with mutations affecting a previously defined CK2 site (PC2S812A) and two candidate AurA sites (PC2S829A and PC2S944A) alone or 
in combination were used in in vitro kinase reactions with recombinant AurA. Phosphoimaging of autoradiographs from three independent experiments was 
quantified (f), and the relative phosphorylation of PC2779–968 mutants was calculated (graph). Data are expressed as mean values ± SEM of three experi-
ments. *, P < 0.001. (g and h) Experiments as in e and f, except recombinant CK2 was used rather than AurA. *, P < 0.001. (i) Lysates from HEK293 cells 
overexpressing Myc-tagged PC2 or the Myc-tagged S829A PC2 mutant (Myc) in the presence or absence of AurA or T288D (catalytically active) AurA 
were used for immunoprecipitation. Cells were treated with 10 µM H89 PKA inhibitor or 500 nM PHA-680632 (PHA) AurA inhibitor for 3 h as indicated. 
RRxS-directed antibody was used to visualize phosphorylation of the S829 residue (phPC2). Western blot of coimmunoprecipitation from three independent 
experiments was quantified (j), and relative phosphorylation of PC2 was calculated. Difference versus PC2: *, P < 0.05. WT, wild type.1029 Aurora A influences calcium signaling • Plotnikova and Golemis
Id2 all have oncogenic functions. We note that the fact that the 
activity of AurA inhibitors was reduced, but not completely 
eliminated, in Pkd2
/ cells suggests that PC2 is an important 
mediator of AurA action in calcium signaling but perhaps not 
the only relevant AurA target; proteins such as the ryanodine 
receptor and inositol­1,4,5­triphosphate receptor are also medi­
ators of release of calcium from the ER (Anyatonwu and Ehrlich, 
2004) and may be influenced by AurA.
Previous studies have identified several regulatory phos­
phorylation sites on PC2. These include phosphorylation by GSK3 
(glycogen synthase kinase 3) at S
76, CK2 at S
812, and protein 
kinase D at S
801 (Cai et al., 2004; Streets et al., 2006, 2010). These 
phosphorylation events affect the localization and Ca
2+ channel 
activity of PC2, its interaction with partners, such as Id2, and the 
ability of PC2 to support cell growth (Cai et al., 2004; Köttgen 
et al., 2005; Li et al., 2005; Streets et al., 2006, 2010). The phos­
phorylation at S
801 within the ER­targeting domain is essential for 
Ca
2+ release from the ER (Streets et al., 2010). In contrast, the 
highly toxic effect of overexpressing the S829A derivative of 
PC2 in cells, which is accompanied by a “collapsed” morphology 
to the ER itself, suggests, as one possibility, that this residue may 
cause gross structural changes in PC2 that damage ER structural 
integrity while not affecting targeting to the ER.
There is a potential therapeutic benefit to identifying ways 
to stimulate PC2 channel activity, and there is an urgent need to 
develop effective therapies for PKD. At present, several targeted 
therapeutic agents are moving through preclinical development 
and clinical trials. Besides c­Src, these include agents targeting 
mammalian target of rapamycin, HER2, and others. These studies 
provide a precedent for adapting drugs originally developed as 
cancer therapeutics in PKD. An obvious concern is that, given the 
chronic but survivable nature of PKD, it is necessary to be ex­
tremely cautious in using powerful compounds that may them­
selves ultimately select for oncogenic changes. However, our data 
suggest that very low doses of an AurA­targeting inhibitor are 
able to enhance PC2 activity, suggesting a basis for further 
investigation of such agents in cases of PKD linked to the PKD1 
mutation, in which PC2 is insufficiently activated but structur­
ally intact. It is also fascinating to note that defects in PKD1 and 
PKD2 have recently been linked to centrosomal amplification 
in both animal models and human patients (Battini et al., 2008; 
Burtey et al., 2008), reducing the separation between cystic syn­
dromes and cancer and, perhaps, supporting the idea that calcium­
dependent activation of AurA is relevant to the severity of PKD 
presentation.  Encouragingly,  a  calcimimetic  drug  was  recently 
shown to have promise in inhibiting cystic growth in PKD (Gattone 
et al., 2009). There is clearly much room for further investigation.
Materials and methods
Plasmids and constructs
Lentiviral constructs were obtained by cloning full-length PKD2 into the 
pLV-CMV-H4-puro vector (provided by P. Chumakov, Russian Academy of 
Sciences,  Moscow,  Russia,  and  A.  Ivanov,  West  Virginia  University, 
Morgantown, WV). PKD2 cloned in pcDNA3.1-Myc was provided by 
S.  Somlo  (Yale  University,  New  Haven,  CT).  The  PKD2-CT  fragment   
(aa 779–968) was cloned into the pEGFP (Takara Bio Inc.) and pGEX-6P1 
vectors (Millipore). Amino acid substitution mutations were introduced 
into wild-type human PKD2 cDNA by site-directed mutagenesis using a 
AurA with PC2, likely by promoting the ability of AurA to 
phosphorylate PC2. Inhibition of AurA by small molecule in­
hibitors enhances PC2 activity, increasing the magnitude of ER 
Ca
2+ release induced by upstream activators. Our findings that 
AurA is abundant and frequently active in normal kidney tissue 
and abnormally expressed in PKD­associated renal cysts to­
gether provide strong evidence that changes in AurA function 
may be relevant to the pathogenesis of PKD.
Interestingly, studies of AurA in cancer have often sug­
gested the pro­oncogenic activity of AurA may arise because its 
overexpression allows a normally centrosomal protein access to 
inappropriate substrates. However, our results suggest changes 
in AurA expression in cancer may promote quantitative changes 
in AurA activity more than qualitative phosphorylation of novel 
substrates. As based on the data presented here, AurA has a 
broader subcellular localization profile in untransformed kidney 
cells than is commonly appreciated, with the centrosome acting 
as a concentration point at which the protein is most readily 
  visualized. This broader view of AurA activity is compatible 
with recent reports that AurA phosphorylates proteins, such as 
RalA (Wu et al., 2005), which are not known for centrosomal lo­
calization (Clough et al., 2002). Our data indicate that not only 
kidney cells but also primary kidney tissue expresses significant 
quantities of AurA in the cytoplasm and nucleus. They further 
show that some of this AurA is activated in noncycling cells in 
normal kidney tissue, particularly in cells of the distal convo­
luted tubules that collect ducts from which cysts arise. AurA ex­
pression and activation are further elevated and anomalous in 
cysts. In this context, it is interesting that two recent studies 
linked AurA to the function of VHL, one showing direct binding 
between the two proteins (Ferchichi et al., 2010), and a second 
showing that mutation of VHL in renal cell carcinoma induces 
both AurA and its partner Nedd9/HEF1 (Xu et al., 2010). Loss 
of VHL is a major lesion responsible for the development of 
renal cell carcinoma, which frequently has associated cysts.
In general, calcium signaling differs significantly in can­
cerous (Roderick and Cook, 2008) and cystic (Harris and Torres, 
2009) cells versus normal cells, promoting increased cell prolif­
eration through the abnormal activation of numerous calcium­
responsive signaling pathways. The fact that AurA activation was 
elevated in PKD­associated cysts is interesting and may reflect 
paradoxical activation in the context of mutated PKD1 and 
PKD2, analogous to the overexpression of growth inhibitory 
proteins in tumors that have eliminated partners in a feedback 
loop. The specific mechanism of AurA activation in this patho­
logical condition bears further investigation. However, based on 
our results, inappropriately activated AurA may act as an inter­
mediate in some of signaling processes relevant to PKD. For ex­
ample, besides binding the PC2 partner Id2, NEDD9 directly 
binds and is both a target and activator of Src kinase (recently 
discussed in Singh et al., 2007). Src signaling is abnormal in 
PKD, and a recent study has indicated that inhibition of Src 
produces clinical benefits in PKD (Sweeney et al., 2008). 
Through interactions with NEDD9, AurA may influence the ac­
tivity of Src and Id2 in either normal renal tissue or in cysts. These 
close physical interactions suggest further topics of study not 
only in renal cysts but also in cancer, in which NEDD9, Src, and JCB • VOLUME 193 • NUMBER 6 • 2011   1030
were used either directly for SDS-PAGE or for immunoprecipitation. Immuno-
precipitation samples were incubated overnight with an antibody at 4°C 
and subsequently incubated for 2 h with protein A/G–Sepharose (Thermo 
Fisher  Scientific),  washed,  and  resolved  by  SDS-PAGE.  GST  pull-down   
assays used wild-type AurA (Millipore) mixed with titrated quantities of 
GST and GST-PC2779–968.
Western blotting was performed using standard procedures and de-
veloped by chemoluminescence using the West Pico system (Thermo 
Fisher Scientific). Primary antibodies included mouse anti-AurA (BD), 
anti-phAurA-T
288 (Cell Signaling Technology), anti-Myc (Santa Cruz Biotech-
nology, Inc.), anti–-actin mAb (AC15; Sigma-Aldrich), and anti-PC2 (G20 
[Santa Cruz Biotechnology, Inc.] and YCC2 [a gift from S. Somlo]). Rabbit 
anti-GFP (ab290; Abcam) was used for immunoprecipitation, and mouse 
anti-GFP (JL-8; BD) was used for Western blotting. Anti-GST mAb (Cell Signal-
ing Technology), polyclonal red anti-Flag M2 affinity gel (EZview; Sigma-
Aldrich), and polyclonal anti-AurA agarose immobilized conjugate (IgM; 
Bethyl)  were  used  for  immunoprecipitations.  Secondary  anti–mouse  and 
anti–rabbit HRP-conjugated antibodies (GE Healthcare) were used at a dilu-
tion of 1:10,000 for visualization of Western blots. Image analysis was per-
formed using ImageJ image processing and analysis software (National 
Institutes of Health) with the signal intensity normalized to -actin or total 
AurA level.
To assess the AurA phosphorylation of PC2 in vivo, Myc-tagged 
PC2 was transiently expressed alone or with AurA or T288D-AurA in 
HEK293 cells and then immunoprecipitated with the anti-Myc antibody. 
Phosphorylation of the S
829 site was assessed by Western blotting with 
Phospho-(Ser/Thr) PKA Substrate Antibody (Cell Signaling Technology). 
500 nM PHA-680632, 4 µM C1368 (Sigma-Aldrich), or 50 nM MLN8237 
(Millennium Pharmaceuticals, Inc.) was used to inhibit AurA, and 10 µM 
H89  PKA  inhibitor  (EMD)  was  used  to  inhibit  phosphorylation.  For   
analysis of PC2 glycosylation, cell lysates were treated with endogly-
cosidase H (New England Biolabs, Inc.) and analyzed by SDS-PAGE 
followed by immunoblotting as previously described (Cai et al., 1999; 
Koulen et al., 2002).
Kinase assays
To assess phosphorylation of PC2 by AurA, an in vitro kinase assay 
was performed using bacterially expressed GST-fused PC2-CT and re-
combinant active AurA or overexpressed AurA immunoprecipitated from 
mammalian cells in standard kinase buffer with the addition of an Mg/ATP 
cocktail  (Millipore).  MBP  (Millipore)  and  histone  H1  (Millipore)  were 
used as positive and negative controls for AurA phosphorylation using 
standard methods. Parallel aliquots without -[
32P]ATP were processed for 
SDS-PAGE/Coomassie staining (Invitrogen). To assess CaM-dependent 
AurA activation, an in vitro kinase assay was performed using AurA puri-
fied from baculovirus or according the protocol described in the previous 
sentence in the presence of 1 µM CaM (EMD) and 1 mM Ca
2+.
Cytosolic Ca
2+ measurements
Cells expressing PC2 constructs were plated on glass coverslips and grown 
to 80% subconfluence. The coverslips were rinsed in HBSS and incu-
bated with 5 µM Fluo-4 AM in HBSS (Invitrogen) in the presence of 0.02% 
pluronic acid (Invitrogen) and 2.5 mM probenecid (Invitrogen) for 20–30 min 
at RT. The coverslips were washed twice in HBSS, mounted in a perfusion 
chamber (FC2; Bioptechs), and analyzed with a microscope (C1 Spectral 
confocal) equipped with an NA 1.40 oil immersion 60× Plan Apochromat 
objective (Nikon) or an NA 1.3 oil immersion 40× Plan Fluo objective 
(Nikon). Images were acquired using EZ-C1 3.8 software at RT in HBSS 
media. Cytosolic Ca
2+ measurements performed in the absence of extracel-
lular Ca
2+ were performed on cells washed and assayed in the aforemen-
tioned  HBSS  except  that  CaCl2  was  omitted  and  0.5  M  EGTA  was 
added. In experiments involving AurA inhibition, cells were treated for 
2–3 h with 500 nM PHA-680632 before calcium measurement. Fluo-4 
was excited at 488 nm, and emission was time-lapse recorded at 522 
nm.  Cells  were  individually  selected,  and  their  fluorescence  intensities 
were normalized to baseline and analyzed with MetaMorph and Meta-
Fluor softwares (Molecular Devices). The area under curve (AUC) was mea-
sured using a standard macro in Excel (Microsoft). For basal intracellular 
calcium measurements, we used the same approach described at the 
beginning of this paragraph.
To compare cellular responses, we examined differences in intensity 
over time using a generalized linear model assuming  distribution and log 
link. We fit the models by generalized estimating of equations assuming an 
autoregressive correlation structure to account for correlation of observa-
tions over time. We included baseline intensity, group, time, and the time–
group interaction in the models. To allow for flexible effects over time, we 
site-directed mutagenesis kit (QuikChange XL; Agilent Technologies). The 
Flag-fused C-terminal domain of PKD1 (aa 4,191–4,302) containing the 
PC1–PC2 interaction site was cloned in the pcDNA3.1(+) vector (Invitrogen). 
Flag- and GST-fused NEDD9 were expressed from the vectors pCatch-Flag 
(O’Neill and Golemis, 2001) and pGEX-2T (Law et al., 1998), respectively. 
AurA  and  derivatives  were  expressed  from  pCMV-SPORT6-C6  (Thermo 
Fisher Scientific) and pcDNA3.1–monomeric RFP vectors. A PCR product of 
monomeric RFP1 was ligated into pcDNA3.1(+) (Invitrogen) to create 
pcDNA3.1–monomeric RFP. pLV-CMV-H4-puro vector, pEFGP, pcDNA3, 
and HA-BioB (an extensively truncated Escherichia coli BioB expressed from 
pcDNA3.1-6HA) were used for negative controls (Singh et al., 2008).
Cell culture and transfection
HEK293 cells were maintained in DME with 10% FBS plus penicillin/strep-
tomycin. LLCPK1 (CRL-1392; American Type Culture Collection) cells were 
maintained in DME/F12 (1:1) with 5% of FBS. The immortalized human 
kidney proximal tubular cell line (HK-2; catalog no. CRL-219; American 
Type Culture Collection) was grown to subconfluence in keratinocyte media 
(Invitrogen). Pkd2
/ and Pkd
+/ were provided by S. Somlo and have been 
previously described (Grimm et al., 2003). PKD1 mutation–containing WT9-7 
(CRL-2830; American Type Culture Collection) and WT9-12 (CRL-2833; 
American  Type  Culture  Collection)  immortalized  epithelial  cells  from   
ADPKD kidney cysts (Loghman-Adham et al., 2003) were grown in DME 
with 10% of FBS on flasks coated with 3 mg/ml bovine collagen type I solu-
tion. We transiently transfected HEK293 cells with expression constructs for 
PKDCT, PKD2, NEDD9, and AurA using Lipofectamine and Plus reagent 
(Invitrogen) according to the manufacturer’s instructions. Cells were used 
for electrophysiological experiments 24–48 h after transfection. For lentivi-
ral infection, pLV constructs were cotransfected with pVSV-G and psPAX2 
into the packaging cell line 293-T. After 24 h, media were collected, fil-
tered through a 0.45-µm polyvinylidene fluoride filter (Millipore), and ap-
plied to HK-2 cells with 8 µg/µl polybrene (Sigma-Aldrich) for 2 d, with 
fresh viral supernatant added every 12 h. After 48 h, cells were lysed, ana-
lyzed by Western blot analysis, and used for further experiments. HK-2 
cells stably expressing PC2 were obtained by infecting the HK-2 cell line 
with the pLV-PKD2 lentiviral vector and then selecting for 6–10 d with 1 mg/ml 
puromycin to produce a mass culture as in Pugacheva and Golemis (2005). 
PC2 expression was verified by immunoblot and immunofluorescence   
analyses. Transient transfection of siRNAs was performed using transfection   
reagent (RNAiMAX; Invitrogen). Cells were assayed after 48 h of transfec-
tion. RNA oligonucleotide duplexes targeted to NEDD9 (Hs_NEDD9_2 
[SI00657370], 5-CGCTGCCGAAATGAAGTATAA-3, and Hs_NEDD9_1 
[SI00657363]) and AurA (Hs_STK6_5 [SI03114111] and Hs_AURKA_1_HP 
[SI00053452], 5-TCCCAGCGCATTCCTTTGCAA-3) were purchased 
from QIAGEN as well as scrambled negative controls. After transfection 
of siRNAs, the degree of depletion of target proteins was determined by 
Western blotting. IC50 determinations with the AurA kinase inhibitor PHA-
680632 (Nerviano Medical Sciences) were performed as in Skobeleva 
et al. (2007).
Immunofluorescence
Cells grown on coverslips were fixed with 4% paraformaldehyde for 10 min 
and then cold methanol for 5 min, permeabilized with 1% Triton X-100 in 
PBS, blocked in PBS with 3% BSA, and incubated with antibodies using 
standard protocols. Primary antibodies included mouse anti-AurA (BD), anti-
acetylated -tubulin mAb (clone 6-11B-1 [Sigma-Aldrich] and clone K(Ac)40 
[Enzo Life Sciences]), anti-PC2 (G20 [Santa Cruz Biotechnology, Inc.] and 
YCC2 [a gift from S. Somlo]), and mouse anti–protein disulfide isomerase 
mAb (Abcam). Secondary antibodies labeled with Alexa Fluor 488, Alexa 
Fluor 568, and DAPI to stain DNA were obtained from Invitrogen. Confocal 
microscopy was performed using a confocal microscope (C1 Spectral; 
Nikon) equipped with an NA 1.40 oil immersion 60× Plan Apochromat ob-
jective (Nikon). Images were acquired at RT using EZ-C1 3.8 (Nikon) soft-
ware and analyzed using the imaging MetaMorph (Molecular Devices) and 
Photoshop (version CS2; Adobe) software. Adjustments to brightness and 
contrast were minimal and were applied to the whole image.
Protein expression, Western blotting, and immunoprecipitation
Recombinant GST, GST fused to aa 779–968 of the PC2 C terminus (GST-
PC2779–968), and NEDD9 (aa 1–363; previously shown to bind and acti-
vate AurA; Pugacheva and Golemis, 2005) were expressed in BL21 (DE3) 
bacteria, induced with IPTG, and purified using a purification module (Micro-
Spin GST; GE Healthcare). Purified recombinant AurA was purchased from 
Millipore. For Western blotting and immunoprecipitation, mammalian cells 
were disrupted in lysis buffer (CelLytic M; Sigma-Aldrich) supplemented 
with a protease and phosphate inhibitor cocktails (Roche). Whole-cell lysates 1031 Aurora A influences calcium signaling • Plotnikova and Golemis
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entered time and the related interactions in the model using restricted cubic 
splines assuming 5 knots (Harrell, 2001). We used Wald tests to assess 
p-values of group effects at each time point.
Immunohistochemistry
All tissue samples examined were institutional review board–consented, 
10–20-mm  sections  of  formalin-fixed,  paraffin-embedded  tissues,  repre-
senting either normal human kidney tissue or kidney tissue from patients di-
agnosed with ADPKD, and archived at the National Disease Resource 
Interchange. Information about PKD1 versus PKD2 mutational status is un-
available, but based on disease prevalence, the majority of cases likely reflect 
mutations in PKD1. Samples analyzed were obtained from eight independent 
patients based on the analysis of a single formalin-fixed, paraffin-embedded 
tissue specimen for each patient. A standard two-stage indirect immunoper-
oxidase staining protocol was used for all tissues (Histostain-Plus kit; Invit-
rogen), with antigen retrieval buffer obtained from BD. As controls, sections 
were stained with diluent alone (5% goat serum in Tris-buffered saline), 
and the antibody was preabsorbed with the immunizing peptide. Incuba-
tions with tissue sections were performed at RT for 1 h or at 4°C overnight, 
and subsequent steps were performed at RT. Sections were counterstained 
with hematoxylin (Sigma-Aldrich). Antibody to total AurA (anti-BTAK anti-
body; provided by T. Gritsko, University of South Florida, Tampa, FL; with 
blocking peptide) was used at a dilution of 1:500, and antibody to phos-
pho-T
288 AurA was used at 1:100 (Bethyl). Images were acquired at 10 
and 40× using a microscope (Eclipse E600; Nikon).
Statistical analysis
Statistical comparisons were made using a two-tailed Student’s t test.   
Experimental values were reported as the means ± SEM. Differences in 
mean values were considered significant at P < 0.05. All calculations of 
statistical  significance  were  made  using  the  InStat  software  package 
(GraphPad Software).
Online supplemental material
Fig. S1 shows controls for AurA antibody inhibition and siRNA specificity. 
Fig. S2 analyzes AurA–NEDD9–PC2 interactions, PC2 localization, and 
expression of PC2 mutants. Fig. S3 shows the analysis of AUC for Fig. 3 (e–j) 
and  Fig.  4  (b  and  c).  Online  supplemental  material  is  available  at 
http://www.jcb.org/cgi/content/full/jcb.201012061/DC1.
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